이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

중추신경계 B세포 림프종 환자 치료에서 자가 줄기세포 이식을 포함하거나 포함하지 않는 병용 화학요법

2026년 8월 31일 업데이트: Alliance for Clinical Trials in Oncology

새로 진단된 원발성 CNS B 세포 림프종에 대한 골수파괴 대 비골수파괴 강화 화학요법의 무작위 2상 시험

The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

Primary Objective:

To compare the two-year progression-free survival (PFS) of patients treated with the myeloablative consolidation treatment strategy of HDT/ASCT versus those treated with non-myeloablative consolidation chemotherapy with cytarabine and etoposide

Secondary Objectives:

  1. To compare the two-year event-free survival (EFS) of patients treated with consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine
  2. To compare the overall survival (OS) of patients treated with the consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine
  3. To assess the toxicities associated with consolidation HDT/ASCT versus consolidation consisting of etoposide and cytarabine
  4. To determine diffusion MRI metrics (ADCmini, ADC25%, and ADCmean) prior to induction chemotherapy, after one full induction chemotherapy cycle, and at the end of induction chemotherapy as a predictor of response and outcome (CALGB 581101)
  5. To determine brain FDG-PET metrics (tumor SUV and tumor versus background SUV) prior to induction chemotherapy, after one full induction chemotherapy cycle, and at the end of induction chemotherapy as a predictor of response and outcome (CALGB 581101)
  6. To determine whether low baseline ADC measurements are associated with shorter PFS and OS (CALGB 581101)
  7. To determine whether reduction in tumor SUV by > 25% on brain FDG-PET/CT after one cycle of induction therapy is associated with improved PFS and OS (CALGB 581101)
  8. To determine which IHC-based biomarkers are predictive of an adverse prognosis (CALGB 151113)
  9. To determine which IHC-based biomarkers are predictive of a favorable prognosis (CALGB 151113) for BCL6 (B-cell CLL/lymphoma 6), and STAT 6 (signal transducer and activator of transcription 6, interleukin-4 induced)
  10. To analyze tumor tissue for gene expression profiles, and to correlate these profiles with treatment outcomes (CALGB 151113)
  11. To determine whether CSF proteome is a predictor of outcomes (prognostic marker) irrespective of treatment arm (CALGB 151113) for (IL-10 (interleukin 10) and C3 (complement component 3)
  12. To assess the neurocognitive function of patients treated with consolidation HDT/ASCT versus those treated with consolidation chemotherapy (etoposide and cytarabine) as measured by serial administration of the International PCNSL Collaborative Group (IPCG) neurocognitive battery and evaluate the long-term survivorship differences between the two arms (CALGB 71105)

연구 유형

중재적

등록 (실제)

113

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 미국
    • Alaska
      • Anchorage, Alaska, 미국, 98508
        • Anchorage Associates in Radiation Medicine
      • Anchorage, Alaska, 미국, 99508
        • Alaska Breast Care and Surgery LLC
      • Anchorage, Alaska, 미국, 99508
        • Alaska Oncology and Hematology LLC
      • Anchorage, Alaska, 미국, 99508
        • Alaska Women's Cancer Care
      • Anchorage, Alaska, 미국, 99508
        • Anchorage Oncology Centre
      • Anchorage, Alaska, 미국, 99508
        • Katmai Oncology Group
      • Anchorage, Alaska, 미국, 99508
        • Providence Alaska Medical Center
      • Anchorage, Alaska, 미국, 99504
        • Anchorage Radiation Therapy Center
    • California
      • Burbank, California, 미국, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • La Jolla, California, 미국, 92093
        • UC San Diego Moores Cancer Center
      • Sacramento, California, 미국, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Francisco, California, 미국, 94115
        • UCSF Medical Center-Mount Zion
      • San Francisco, California, 미국, 94143
        • UCSF Medical Center-Parnassus
    • Connecticut
      • New Haven, Connecticut, 미국, 06520
        • Yale University
    • Florida
      • Tampa, Florida, 미국, 33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • Emory University/Winship Cancer Institute
    • Idaho
      • Boise, Idaho, 미국, 83712
        • Saint Luke's Mountain States Tumor Institute
      • Fruitland, Idaho, 미국, 83619
        • Saint Luke's Mountain States Tumor Institute - Fruitland
      • Meridian, Idaho, 미국, 83642
        • Saint Luke's Mountain States Tumor Institute - Meridian
      • Nampa, Idaho, 미국, 83686
        • Saint Luke's Mountain States Tumor Institute - Nampa
      • Twin Falls, Idaho, 미국, 83301
        • Saint Luke's Mountain States Tumor Institute-Twin Falls
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, 미국, 60612
        • University of Illinois
    • Indiana
      • Richmond, Indiana, 미국, 47374
        • Reid Health
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • University of Kansas Cancer Center
    • Kentucky
      • Crestview Hills, Kentucky, 미국, 41017
        • Oncology Hematology Care Inc-Crestview
    • Louisiana
      • New Orleans, Louisiana, 미국, 70112
        • Tulane University Health Sciences Center
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, 미국, 02115
        • Brigham and Women's Hospital
      • Boston, Massachusetts, 미국, 02114
        • Massachusetts General Hospital Cancer Center
    • Michigan
      • Battle Creek, Michigan, 미국, 49017
        • Bronson Battle Creek
      • Grand Rapids, Michigan, 미국, 49503
        • Spectrum Health at Butterworth Campus
      • Grand Rapids, Michigan, 미국, 49503
        • Mercy Health Saint Mary's
      • Kalamazoo, Michigan, 미국, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, 미국, 49007
        • Bronson Methodist Hospital
      • Kalamazoo, Michigan, 미국, 49001
        • Borgess Medical Center
      • Muskegon, Michigan, 미국, 49444
        • Mercy Health Mercy Campus
      • Niles, Michigan, 미국, 49120
        • Lakeland Community Hospital
      • Reed City, Michigan, 미국, 49677
        • Spectrum Health Reed City Hospital
      • Saint Joseph, Michigan, 미국, 49085
        • Marie Yeager Cancer Center
      • Saint Joseph, Michigan, 미국, 49085
        • Lakeland Hospital
      • Traverse City, Michigan, 미국, 49684
        • Munson Medical Center
      • Wyoming, Michigan, 미국, 49519
        • Metro Health Hospital
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
    • Nebraska
      • Omaha, Nebraska, 미국, 68198
        • University of Nebraska Medical Center
    • New York
      • New York, New York, 미국, 10065
        • Weill Medical College of Cornell University
      • Rochester, New York, 미국, 14642
        • University of Rochester
      • Stony Brook, New York, 미국, 11794
        • Stony Brook University Medical Center
      • Syracuse, New York, 미국, 13210
        • State University of New York Upstate Medical University
    • North Carolina
      • Durham, North Carolina, 미국, 27710
        • Duke University Medical Center
    • Ohio
      • Centerville, Ohio, 미국, 45459
        • Dayton Physicians LLC-Miami Valley South
      • Cincinnati, Ohio, 미국, 45242
        • Oncology Hematology Care Inc-Blue Ash
      • Cincinnati, Ohio, 미국, 45202
        • Oncology Hematology Care Inc-Eden Park
      • Cincinnati, Ohio, 미국, 45211
        • Oncology Hematology Care Inc-Mercy West
      • Cincinnati, Ohio, 미국, 45236
        • Oncology Hematology Care Inc-Kenwood
      • Cincinnati, Ohio, 미국, 45230
        • Oncology Hematology Care Inc - Anderson
      • Dayton, Ohio, 미국, 45406
        • Good Samaritan Hospital - Dayton
      • Dayton, Ohio, 미국, 45409
        • Miami Valley Hospital
      • Dayton, Ohio, 미국, 45415
        • Dayton Physicians LLC-Samaritan North
      • Dayton, Ohio, 미국, 45415
        • Samaritan North Health Center
      • Dayton, Ohio, 미국, 45420
        • Dayton NCI Community Oncology Research Program
      • Fairfield, Ohio, 미국, 45014
        • Oncology Hematology Care Inc-Healthplex
      • Findlay, Ohio, 미국, 45840
        • Blanchard Valley Hospital
      • Findlay, Ohio, 미국, 45840
        • Armes Family Cancer Center
      • Findlay, Ohio, 미국, 45840
        • Orion Cancer Care
      • Franklin, Ohio, 미국, 45005-1066
        • Atrium Medical Center-Middletown Regional Hospital
      • Franklin, Ohio, 미국, 45005
        • Dayton Physicians LLC-Atrium
      • Greenville, Ohio, 미국, 45331
        • Wayne Hospital
      • Greenville, Ohio, 미국, 45331
        • Dayton Physicians LLC-Wayne
      • Kettering, Ohio, 미국, 45429
        • Kettering Medical Center
      • Kettering, Ohio, 미국, 45409
        • Greater Dayton Cancer Center
      • Middletown, Ohio, 미국, 45042
        • Dayton Physicians LLC-Signal Point
      • Sidney, Ohio, 미국, 45365
        • Dayton Physicians LLC-Wilson
      • Springfield, Ohio, 미국, 45505
        • Springfield Regional Medical Center
      • Springfield, Ohio, 미국, 45504
        • Springfield Regional Cancer Center
      • Troy, Ohio, 미국, 45373
        • Upper Valley Medical Center
      • Troy, Ohio, 미국, 45373
        • Dayton Physicians LLC-Upper Valley
    • Oklahoma
      • Tulsa, Oklahoma, 미국, 74136
        • Surgical Associates Inc
      • Tulsa, Oklahoma, 미국, 74146
        • Warren Clinic Oncology-Tulsa
    • Oregon
      • Bend, Oregon, 미국, 97701
        • Saint Charles Health System
      • Clackamas, Oregon, 미국, 97015
        • Clackamas Radiation Oncology Center
      • Clackamas, Oregon, 미국, 97015
        • Providence Oncology and Hematology Care Southeast
      • Coos Bay, Oregon, 미국, 97420
        • Bay Area Hospital
      • Milwaukie, Oregon, 미국, 97222
        • Providence Milwaukie Hospital
      • Newberg, Oregon, 미국, 97132
        • Providence Newberg Medical Center
      • Oregon City, Oregon, 미국, 97045
        • Providence Willamette Falls Medical Center
      • Portland, Oregon, 미국, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, 미국, 97225
        • Providence Saint Vincent Medical Center
    • Pennsylvania
      • Danville, Pennsylvania, 미국, 17822
        • Geisinger Medical Center
      • Lewistown, Pennsylvania, 미국, 17044
        • Lewistown Hospital
      • Pittsburgh, Pennsylvania, 미국, 15232
        • University of Pittsburgh Cancer Institute (UPCI)
    • Utah
      • Salt Lake City, Utah, 미국, 84112
        • Huntsman Cancer Institute/University of Utah
    • Vermont
      • Berlin Corners, Vermont, 미국, 05602
        • Central Vermont Medical Center/National Life Cancer Treatment
      • Burlington, Vermont, 미국, 05401
        • University of Vermont Medical Center
      • Burlington, Vermont, 미국, 05405
        • University of Vermont College of Medicine
    • Virginia
      • Richmond, Virginia, 미국, 23298
        • Virginia Commonwealth University/Massey Cancer Center
    • Washington
      • Aberdeen, Washington, 미국, 98520
        • Providence Regional Cancer System-Aberdeen
      • Anacortes, Washington, 미국, 98221
        • Cancer Care Center at Island Hospital
      • Bellevue, Washington, 미국, 98005
        • Swedish Cancer Institute-Eastside Oncology Hematology
      • Bellingham, Washington, 미국, 98225
        • PeaceHealth Saint Joseph Medical Center
      • Centralia, Washington, 미국, 98531
        • Providence Regional Cancer System-Centralia
      • Edmonds, Washington, 미국, 98026
        • Swedish Medical Center-Edmonds
      • Everett, Washington, 미국, 98201
        • Providence Regional Cancer Partnership
      • Issaquah, Washington, 미국, 98029
        • Swedish Cancer Institute-Issaquah
      • Lacey, Washington, 미국, 98503
        • Providence Regional Cancer System-Lacey
      • Longview, Washington, 미국, 98632
        • PeaceHealth Saint John Medical Center
      • Seattle, Washington, 미국, 98109
        • Fred Hutchinson Cancer Research Center
      • Seattle, Washington, 미국, 98109
        • Seattle Cancer Care Alliance
      • Seattle, Washington, 미국, 98195
        • University of Washington Medical Center
      • Seattle, Washington, 미국, 98107
        • Swedish Medical Center-Ballard Campus
      • Seattle, Washington, 미국, 98104
        • Minor and James Medical PLLC
      • Seattle, Washington, 미국, 98104
        • Pacific Gynecology Specialists
      • Seattle, Washington, 미국, 98112
        • Group Health Cooperative-Seattle
      • Seattle, Washington, 미국, 98122-4307
        • Swedish Medical Center-First Hill
      • Shelton, Washington, 미국, 98584
        • Providence Regional Cancer System-Shelton
      • Spokane, Washington, 미국, 99204
        • Rockwood Cancer Treatment Center-DHEC-Downtown
      • Spokane Valley, Washington, 미국, 99216
        • Rockwood Clinic Cancer Treatment Center-Valley
      • Vancouver, Washington, 미국, 98664
        • PeaceHealth Southwest Medical Center
      • Vancouver, Washington, 미국, 98684
        • Compass Oncology Vancouver
      • Walla Walla, Washington, 미국, 99362
        • Providence Saint Mary Regional Cancer Center
      • Yakima, Washington, 미국, 98902
        • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
      • Yelm, Washington, 미국, 98597
        • Providence Regional Cancer System-Yelm
    • Wisconsin
      • La Crosse, Wisconsin, 미국, 54601
        • Mayo Clinic Health System-Franciscan Healthcare
      • Madison, Wisconsin, 미국, 53792
        • University of Wisconsin Hospital and Clinics

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

  1. Documentation of Disease: Diagnosis of primary CNS diffuse large B-cell lymphoma confirmed by one of the following: brain biopsy or resection, cerebrospinal fluid and vitreous fluid.
  2. Other Lymphomas: Patients must have no evidence or history of non-Hodgkin lymphoma (NHL) outside of CNS.
  3. Previous Treatment: Patients must have no prior chemotherapy or radiation therapy for lymphoma.
  4. Age- Patients must be between the ages of 18 and 75 years.
  5. Karnofsky Performance Scale - Patients must measure Karnofsky Performance Scale ≥ 30 (≥ 50 for patients ages 60-70).
  6. Pregnancy and Nursing Status - Patients must be non-pregnant and non-nursing; women of childbearing potential must have a negative serum or urine pregnancy test 10-14 days prior to registration; in addition, women and men of childbearing potential must commit to use an effective form of contraception throughout their participation in this study; appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives, or double barrier method (diaphragm plus condom)
  7. HIV - Patients must have negative HIV serology.
  8. Hepatitis - Patients must have negative HCV serology (unless HBsAb positive patient has recently received HBV vaccine, in this case HBcAb should be negative). All patients must be screened for hepatitis B infection before starting treatment. Those patients who test positive for hepatitis B should be closely monitored for evidence of active HBV infection and hepatitis during and for several months after rituximab treatment. PCNSL patients with a history of hepatitis B infection should be treated with entecavir or lamivudine (physician discretion for choice of drug) as antiviral prophylaxis to prevent hepatitis B reactivation.
  9. Organ Transplant or Immunosuppressant Therapy - Patient must have no history of organ transplantation or ongoing immunosuppressant therapy.
  10. Required Initial Laboratory Values: ANC ≥ 1500/mcL, AST and ALT < 2 x upper limit of normal (ULN), total bilirubin ≤ 3 mg/dL, creatinine clearance ≥ 50 mL/min, platelet count ≥ 100,000/mcL

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
다른: Arm I

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.
의약품: G-CSF
절차: 줄기 세포 이식
의약품: carmustine

Given IV

의약품: thiotepa

Given IV
다른: Arm II

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.
의약품: G-CSF
의약품: cytarabine

Given IV

의약품: etoposide

Given IV

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression Free Survival
기간: 2 years

The primary endpoint is to compare the two-year progression-free survival (PFS) of patients treated with the myeloablative consolidation treatment strategy of HDT/ASCT versus those treated with non-myeloablative consolidation chemotherapy with cytarabine and etoposide.

PFS time = time from Registration to earliest date of Progression or Death due to any cause, censoring non-progressed and alive patients at the date of last disease status evaluation.

Response will be defined using the modified IPCG criteria. Progressive disease is defined as > 25% increase in contrast-enhancing CNS (brain and spine if latter abnormal at baseline) disease, appearance of any new, measurable (>/= 10mm) contrast-enhancing disease or recurrent or new ocular or CSF disease.
2 years

2차 결과 측정

결과 측정
측정값 설명
기간
Event Free Survival
기간: 2 years

To compare the two-year event-free survival (EFS) of patients treated with consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine.

EFS event = same definition as PFS with non-protocol treatment also considered an event
2 years
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
기간: 7 years

Number of patients reporting at least one adverse event at least possibly related to treatment.
7 years
Overall Survival
기간: 2 years

To compare the overall survival (OS) of patients treated with the consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine.

OS event = Registration/Randomization to Death due to any cause
2 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Alliance for Clinical Trials in Oncology

협력자

National Cancer Institute (NCI)

수사관

  • 연구 의자: Tracy Batchelor, MD, MPH, Massachusetts General Hospital

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2012년 9월 1일

기본 완료 (실제)

2021년 1월 14일

연구 완료 (실제)

2022년 2월 24일

연구 등록 날짜

최초 제출

2012년 1월 13일

QC 기준을 충족하는 최초 제출

2012년 1월 13일

처음 게시됨 (추정된)

2012년 1월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 31일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • CALGB-51101
  • CDR0000721927 (레지스트리 식별자: NCI Physician Data Query)
  • NCI-2012-00110 (레지스트리 식별자: NCI Clinical Trial Reporting Program)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다